The NY Times reports regulators have approved Amgen’s new drug called Nplate, which treats a rare blood clotting disorder that affects about 140,000 people. The disorder causes the body to attack platelets, which are tiny components that help with blood clotting. The drug will encourage platelet production by stimulating patient’s bone marrow.
There are some risks to taking the drug so regulators will require all patients to enroll in a long-term safety study. Some patients who have enrolled in the study have developed leukemia due to bone-marrow abnormalities. More studies will need to be done though to determine whether the development of leukemia may relate to the use of Nplate.
No comments:
Post a Comment